C Ola Landgren, Leader, Translational and Clinical Oncology Program/Experimental Therapeutics at Sylvester Comprehensive Cancer Center, shared a post on LinkedIn:
“Today, the U.S. Food and Drug Administration (FDA) approved GSK’s drug, Blenrep, in one combination regimen, clearing the way for its return to the market almost 3 years after it was taken off the market.
The FDA approved Blenrep in combination with Bortezomib and Dexamethasone for patients with relapsed/refractory multiple myeloma who have received at least 2 prior lines of therapy, including a Proteasome inhibitor and an immunomodulatory agent.
A second regimen, pairing Blenrep with Pomalidomide and Dexamethasone, which was tested in a separate trial, was not included in the approval.”
More posts featuring C Ola Landgren on OncoDaily.